A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

Mg0020 50090, Winston-Salem

Mg0020 50092, Orange

Mg0020 50099, San Francisco

Mg0020 50561, Lexington

Mg0020 50560, Edmonton

Mg0020 50069, Toronto

Mg0020 20161, Tbilisi

Mg0020 20165, Tbilisi

Mg0020 20305, Tbilisi

Mg0020 40140, Göttingen

Mg0020 40177, Münster

Mg0020 40144, Milan

Mg0020 40146, Pavia

Mg0020 40150, Roma

Mg0020 20068, Chiba

Mg0020 20078, Hanamaki-shi

Mg0020 20077, Sendai

Mg0020 20076, Shinjuku-ku

Mg0020 40155, Gdansk

Mg0020 40727, Lodz

Mg0020 40153, Poznan

Mg0020 40729, Niš

Mg0020 40160, Barcelona

Mg0020 40267, Barcelona

Mg0020 40308, San Sebastián de los Reyes

Mg0020 40168, Nottingham

Mg0020 40163, Oxford